Product Description
Atomoxetine is used as part of a total treatment program to increase the ability to pay attention and decrease impulsiveness and hyperactivity in children and adults with ADHD. Atomoxetine is in a class of medications called selective norepinephrine reuptake inhibitors (Sourced from: https://medlineplus.gov/druginfo/meds/a603013.html)
Mechanisms of Action: NRI Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: None
Company: Eli Lilly
Company Location: Eastern America
Company Founding Year: 1876
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Japan, United Kingdom, United States
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Alzheimer Disease|Sleep Apnea, Obstructive
Phase 2: Rett Syndrome|Tourette Syndrome
Phase 1: Attention Deficit Disorder with Hyperactivity
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2019-004455-36 |
ATO-TS | P2 |
Active, not recruiting |
Rett Syndrome|Tourette Syndrome |
2022-07-10 |
2022-03-13 |
Treatments |
|
NCT07724132 |
AD-SMART | P3 |
Recruiting |
Alzheimer Disease |
2031-03-01 |
2026-07-24 |
Primary Endpoints|Treatments |
|
NCT06566820 |
APC-APN-306 | P3 |
Enrolling by invitation |
Sleep Apnea, Obstructive |
2026-06-30 |
2024-09-26 |
Primary Endpoints |
|
JapicCTI-101245 |
JapicCTI-101245 | P1 |
Active |
Attention Deficit Disorder with Hyperactivity |
None |
|||
NCT04939168 |
MARIPOSA | P2 |
Not yet recruiting |
Sleep Apnea, Obstructive |
2022-04-01 |
2021-06-26 |
Primary Endpoints|Treatments |